IMUX vs. AGLE, VERV, ERAS, BMEA, LXRX, NGNE, TBPH, TERN, SLRN, and ESPR
Should you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Aeglea BioTherapeutics (AGLE), Verve Therapeutics (VERV), Erasca (ERAS), Biomea Fusion (BMEA), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Acelyrin (SLRN), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical preparations" industry.
Immunic (NASDAQ:IMUX) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk.
Immunic has a net margin of 0.00% compared to Aeglea BioTherapeutics' net margin of -22,195.36%. Aeglea BioTherapeutics' return on equity of -132.05% beat Immunic's return on equity.
Immunic presently has a consensus target price of $8.50, suggesting a potential upside of 585.48%. Aeglea BioTherapeutics has a consensus target price of $17.50, suggesting a potential upside of ∞. Given Aeglea BioTherapeutics' higher probable upside, analysts clearly believe Aeglea BioTherapeutics is more favorable than Immunic.
51.8% of Immunic shares are owned by institutional investors. 3.0% of Immunic shares are owned by company insiders. Comparatively, 6.6% of Aeglea BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Aeglea BioTherapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunic had 2 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 2 mentions for Immunic and 0 mentions for Aeglea BioTherapeutics. Immunic's average media sentiment score of 0.29 beat Aeglea BioTherapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media.
Aeglea BioTherapeutics received 160 more outperform votes than Immunic when rated by MarketBeat users. However, 65.73% of users gave Immunic an outperform vote while only 56.70% of users gave Aeglea BioTherapeutics an outperform vote.
Immunic has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
Summary
Immunic beats Aeglea BioTherapeutics on 9 of the 17 factors compared between the two stocks.
Get Immunic News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
